Akeso’s Phase 3 ASCO data show ivonescimab improved overall survival vs PD-1 chemo in squamous NSCLC—key read for investors.

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan ...

Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...

Systemic therapy was administered to 46.8% of older mNSCLC patients; chemotherapy predominated (95.3% of treated), with immunotherapy (22.6%) and targeted therapy (15.3%) used less frequently. Early ...

Many cancers can often be treated successfully when detected early. Surgery, radiation and chemotherapy are all powerful tools to remove or destroy tumors in their original location. However, when ...